Aileen Baker Felton

Array ( [id] => 12641160 [patent_doc_number] => 20180105551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-19 [patent_title] => TRINUCLEOTIDE MRNA CAP ANALOGS [patent_app_type] => utility [patent_app_number] => 15/788742 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15788742 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413177 [patent_doc_number] => 20180258131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/787140 [patent_app_country] => US [patent_app_date] => 2017-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7792 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15787140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14169303 [patent_doc_number] => 10258638 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Administration of nicotinamide mononucleotide in the treatment of disease [patent_app_type] => utility [patent_app_number] => 15/783845 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 94 [patent_figures_cnt] => 178 [patent_no_of_words] => 34488 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15783845 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16175473 [patent_doc_number] => 20200222441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-16 [patent_title] => INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE [patent_app_type] => utility [patent_app_number] => 16/338975 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34856 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16338975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12603321 [patent_doc_number] => 20180092937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-05 [patent_title] => CYCLIC DINUCLEOTIDE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 15/716720 [patent_app_country] => US [patent_app_date] => 2017-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17261 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15716720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844903 [patent_doc_number] => 11434255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Nucleoside and nucleotide analogues bearing a quaternary all-carbon stereogenic center at the 2' position and methods of use as a cardioprotective agent [patent_app_type] => utility [patent_app_number] => 16/333673 [patent_app_country] => US [patent_app_date] => 2017-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 13 [patent_no_of_words] => 22461 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333673 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14040699 [patent_doc_number] => 20190076456 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => COMPOSITIONS AND METHODS FOR LIVER DISEASES [patent_app_type] => utility [patent_app_number] => 15/702528 [patent_app_country] => US [patent_app_date] => 2017-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15702528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12240147 [patent_doc_number] => 20180073011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-15 [patent_title] => 'METHODS AND COMPOSITIONS FOR PURIFYING DOUBLE STRANDED NUCLEIC ACIDS' [patent_app_type] => utility [patent_app_number] => 15/702363 [patent_app_country] => US [patent_app_date] => 2017-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6862 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15702363 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12260577 [patent_doc_number] => 20180079773 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-22 [patent_title] => 'PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS' [patent_app_type] => utility [patent_app_number] => 15/697136 [patent_app_country] => US [patent_app_date] => 2017-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20988 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15697136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17800374 [patent_doc_number] => 11414659 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-16 [patent_title] => 4'-phosphate analogs and oligonucleotides comprising the same [patent_app_type] => utility [patent_app_number] => 16/328546 [patent_app_country] => US [patent_app_date] => 2017-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 21 [patent_no_of_words] => 24162 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16328546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14682265 [patent_doc_number] => 20190240247 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => PHARMACEUTICAL FORMULATIONS OF REGADENOSON [patent_app_type] => utility [patent_app_number] => 16/329864 [patent_app_country] => US [patent_app_date] => 2017-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2050 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16329864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17742585 [patent_doc_number] => 11390642 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-19 [patent_title] => Compositions comprising reversibly modified oligonucleotides and uses thereof [patent_app_type] => utility [patent_app_number] => 16/325979 [patent_app_country] => US [patent_app_date] => 2017-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 35595 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 602 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16325979 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12049824 [patent_doc_number] => 20170326167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-16 [patent_title] => 'Compositions and Methods for Treating an Infection' [patent_app_type] => utility [patent_app_number] => 15/664527 [patent_app_country] => US [patent_app_date] => 2017-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56963 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15664527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15753671 [patent_doc_number] => 10618931 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-14 [patent_title] => Method for solution phase detritylation of oligomeric compounds [patent_app_type] => utility [patent_app_number] => 15/661319 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13476 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 98 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12031110 [patent_doc_number] => 20170321209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'METHOD FOR ISOLATING DNA' [patent_app_type] => utility [patent_app_number] => 15/654634 [patent_app_country] => US [patent_app_date] => 2017-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3679 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15654634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14464459 [patent_doc_number] => 20190183869 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-20 [patent_title] => TREATMENT OF FABRY DISEASE IN ERT-NAIVE AND ERT-EXPERIENCED PATIENTS [patent_app_type] => utility [patent_app_number] => 16/318905 [patent_app_country] => US [patent_app_date] => 2016-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16318905 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14621917 [patent_doc_number] => 20190224326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-25 [patent_title] => NUCLEIC ACID CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/317229 [patent_app_country] => US [patent_app_date] => 2017-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16317229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023637 [patent_doc_number] => 20170313736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'MUTAGENIC NUCLEOSIDE ANALOGS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/642402 [patent_app_country] => US [patent_app_date] => 2017-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 32050 [patent_no_of_claims] => 110 [patent_no_of_ind_claims] => 57 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15642402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15395805 [patent_doc_number] => 10538546 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-21 [patent_title] => Solid-phase purification of synthetic nucleic acid sequences [patent_app_type] => utility [patent_app_number] => 16/312445 [patent_app_country] => US [patent_app_date] => 2017-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 57 [patent_no_of_words] => 19187 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16312445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12728734 [patent_doc_number] => 20180134745 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-17 [patent_title] => METHODS OF SYNTHESIZING SUBSTITUTED PURINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 15/635032 [patent_app_country] => US [patent_app_date] => 2017-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51443 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15635032 [rel_patent_id] =>[rel_patent_doc_number] =>)